These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 7495285)

  • 1. Absence of RET proto-oncogene point mutations in sporadic hyperplastic and neoplastic lesions of the parathyroid gland.
    Padberg BC; Schröder S; Jochum W; Kastendieck H; Roth J; Heitz PU; Komminoth P
    Am J Pathol; 1995 Dec; 147(6):1600-7. PubMed ID: 7495285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
    Komminoth P
    Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RET proto-oncogene point mutations in sporadic neuroendocrine tumors.
    Komminoth P; Roth J; Muletta-Feurer S; Saremaslani P; Seelentag WK; Heitz PU
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2041-6. PubMed ID: 8964826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
    Komminoth P; Kunz EK; Matias-Guiu X; Hiort O; Christiansen G; Colomer A; Roth J; Heitz PU
    Cancer; 1995 Aug; 76(3):479-89. PubMed ID: 8625130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the RET proto-oncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2.
    Pausova Z; Soliman E; Amizuka N; Janicic N; Konrad EM; Arnold A; Goltzman D; Hendy GN
    J Clin Endocrinol Metab; 1996 Jul; 81(7):2711-8. PubMed ID: 8675600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of RET proto-oncogene point mutations in paraffin-embedded pheochromocytoma specimens by nonradioactive single-strand conformation polymorphism analysis and direct sequencing.
    Komminoth P; Kunz E; Hiort O; Schröder S; Matias-Guiu X; Christiansen G; Roth J; Heitz PU
    Am J Pathol; 1994 Oct; 145(4):922-9. PubMed ID: 7943181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple endocrine neoplasia type 2-associated RET proto-oncogene mutations do not contribute to the pathogenesis of sporadic parathyroid tumors.
    Willeke F; Hauer MP; Buchcik R; Gebert JF; Hahn M; Fitze G; Mechtersheimer G; Möller P; Saeger HD; Herfarth C; Schackert HK
    Surgery; 1998 Sep; 124(3):484-90. PubMed ID: 9736899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations.
    Kambouris M; Jackson CE; Feldman GL
    Hum Mutat; 1996; 8(1):64-70. PubMed ID: 8807338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (Sipple's syndrome).
    Oishi S; Sato T; Takiguchi-Shirahama S; Nakamura Y
    Endocr J; 1995 Aug; 42(4):527-36. PubMed ID: 8556060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours.
    Eng C; Smith DP; Mulligan LM; Nagai MA; Healey CS; Ponder MA; Gardner E; Scheumann GF; Jackson CE; Tunnacliffe A
    Hum Mol Genet; 1994 Feb; 3(2):237-41. PubMed ID: 7911697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A, MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A.
    Landsvater RM; Jansen RP; Hofstra RM; Buys CH; Lips CJ; Ploos van Amstel HK
    Hum Genet; 1996 Jan; 97(1):11-4. PubMed ID: 8557249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the RET proto-oncogene in sporadic parathyroid adenomas.
    Williams GH; Rooney S; Carss A; Cummins G; Thomas GA; Williams ED
    J Pathol; 1996 Oct; 180(2):138-41. PubMed ID: 8976870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular analysis of the RET proto-oncogene in patients with sporadic medullary thyroid carcinoma: a novel point mutation in the extracellular cysteine-rich domain.
    Bugalho MJ; Frade JP; Santos JR; Limbert E; Sobrinho L
    Eur J Endocrinol; 1997 Apr; 136(4):423-6. PubMed ID: 9150704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germ line mutations of the ret proto-oncogene in Japanese patients with multiple endocrine neoplasia type 2A and type 2B.
    Maruyama S; Iwashita T; Imai T; Funahashi H; Ceccherini I; Luo Y; Romeo G; Matsuo S; Matsuyama M; Takahashi M
    Jpn J Cancer Res; 1994 Sep; 85(9):879-82. PubMed ID: 7961113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of mutations in the MEN2A region of the ret proto-oncogene in non-MEN 2A phaeochromocytomas.
    Chew SL; Lavender P; Jain A; Weber A; Ross RJ; Wass JA; Besser GM; Clark AJ
    Clin Endocrinol (Oxf); 1995 Jan; 42(1):17-21. PubMed ID: 7889627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Detection of RET-proto-oncogene mutations in the diagnosis of Type 2 endocrine neoplasia (MEN 2)].
    Komminoth P; Muletta-Feurer S; Soltermann A; Gemsenjäger E; Bürgi H; Staub JJ; Schönle E; Fried M; Vetter W; Spinas GA; Heitz PU
    Schweiz Med Wochenschr; 1996 Aug; 126(31-32):1329-38. PubMed ID: 8765374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational analysis of the RET proto-oncogene in 71 Japanese patients with medullary thyroid carcinoma.
    Shirahama S; Ogura K; Takami H; Ito K; Tohsen T; Miyauchi A; Nakamura Y
    J Hum Genet; 1998; 43(2):101-6. PubMed ID: 9621513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The RET protooncogene in sporadic pheochromocytomas: frequent MEN 2-like mutations and new molecular defects.
    Beldjord C; Desclaux-Arramond F; Raffin-Sanson M; Corvol JC; De Keyzer Y; Luton JP; Plouin PF; Bertagna X
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2063-8. PubMed ID: 7608256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of somatic RET gene mutation in sporadic parathyroid tumors and hyperplasia secondary to uremia, and absence of somatic Men1 gene mutation in MEN2A-associated hyperplasia.
    Uchino S; Noguchi S; Nagatomo M; Sato M; Yamashita H; Yamashita H; Watanabe S; Murakami T; Toda M; Wakiya S; Adachi M
    Biomed Pharmacother; 2000 Jun; 54 Suppl 1():100s-103s. PubMed ID: 10915003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC:s.
    Zedenius J; Wallin G; Hamberger B; Nordenskjöld M; Weber G; Larsson C
    Hum Mol Genet; 1994 Aug; 3(8):1259-62. PubMed ID: 7987299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.